This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Access the science, technology and contacts that you need to accelerate your biologics and novel products towards commercial success.

Modeling virus clearance

Share this article

To determine the viral-clearance efficacy of biomanufacturing steps, live mammalian viruses are “spiked” into in-process solutions, then processed and analyzed for viral reduction. Because live viruses are infectious, such “spiking studies” typically are conducted in specialized biosafety facilities. The associated costs and logistics limit viral clearance analysis during early process development and characterization.

In this deep dive from BioProcess International, authors from GSK and MockV Solutions describe the use of a noninfectious virus particle as an economical spiking surrogate. They report results from an anion-exchange design of experiments (DoE)study comparing clearance of the model with that of the live, infectious alternative.

Read the full article here. 

Share this article

Upcoming event

BioProcess International Europe

09 - 12 May 2023, RAI in Amsterdam

Europe’s Leading BioProcessing Event for Accelerating Next Generation mAbs, Novel Modalities and ATMPs to Commercial Success

Go to site